Oncoinvent (ONCIN) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
8 Jan, 2026Opening remarks and agenda
Chair welcomed shareholders and guests, proposed Hans Cappelen Arnesen as meeting chair, and outlined the agenda.
Election of chair and co-signer of minutes approved; notice and agenda confirmed as distributed in accordance with regulations.
Specific resolutions to be voted on
Approved a small share capital increase to facilitate a 100-to-1 reverse share split, aiming to avoid penny stock status and attract professional investors.
Approved reduction of nominal share value from NOK 0.50 to NOK 0.25 to provide flexibility for future equity raises.
Authorized the board to increase share capital for employee options, board RSUs/options, and general purposes.
Shareholder proposals specific to EGM
Shareholders questioned the rationale for the 100-to-1 split and the choice of NOK 0.25 nominal value, seeking clarity on future capital raise flexibility.
Latest events from Oncoinvent
- Strong clinical progress, merger, and NOK 130M raise deliver NOK 180M cash and runway into 2027.ONCIN
Q4 202526 Feb 2026 - Bemcentinib advances in STK11-mutated NSCLC, with strong safety, lower costs, and solid cash runway.ONCIN
Q3 20243 Feb 2026 - Phase 2a in STK11m NSCLC advances, fully funded, with key data and Tempus control arm ahead.ONCIN
Q2 202423 Jan 2026 - Lead NSCLC study halted; strategic review and cost-saving measures underway.ONCIN
Q4 202423 Dec 2025 - All resolutions, including a NOK 130 million rights issue, passed with near-unanimous approval.ONCIN
EGM 20255 Dec 2025 - Merger forms a leading radiopharma company with strong funding, market focus, and growth potential.ONCIN
M&A Announcement14 Nov 2025 - Merger, rights issue, and strong trial results extend runway and accelerate phase II recruitment.ONCIN
Q3 20254 Nov 2025 - Merger with Oncoinvent ASA and rights issue mark a new phase after clinical program closures.ONCIN
Q2 202520 Aug 2025 - Merger forms a well-funded radiopharma leader focused on peritoneal metastases and clinical milestones.ONCIN
M&A Announcement2 Jul 2025